In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Pramlintide (Symlin) | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 595 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 84 (78 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 59 · 3 active5 more mention it but do not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Symlin says: “Adjunctive treatment for patients with type 1 or type 2 diabetes who use mealtime insulin”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pramlintide (Symlin) | Liraglutide |
|---|---|---|
| Glycemic controlNervous system and cognition | 21220552 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 53458 | 83481717 |
|---|
| Adverse eventsWhole body | 514821 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 2525 | 185185 |
|---|
| LipidsNervous system and cognition | 13112 | 14313733 |
|---|
| Cardiovascular eventsCardiovascular | 22 | 13313111 |
|---|
| Appetite and food intakeMetabolic and weight | 462224 | 1129517 |
|---|
| Blood pressureCardiovascular | 11 | 1201182 |
|---|
| Inflammation markersNervous system and cognition | 5311 | 117100152 |
|---|
| PharmacokineticsPharmacology | 141031 | 969231 |
|---|
| Receptor activity and mechanismWhole body | 309318 | 8250626 |
|---|
| Gastrointestinal motilityGastrointestinal | 2525 | 26251 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Pramlintide (Symlin) differs from Amylin at 3 positions and carries 1 added group.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 59 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
AstraZeneca112 participantsMay 2007 to Apr 2008
Type 2 Diabetes Mellitus
Albert Einstein College of Medicine37 participantsAug 2009 to Dec 2016
Type 1 Diabetes
University of Texas Southwestern Medical Center33 participantsNov 2007 to Aug 2011
Schizophrenia · Schizoaffective Disorder · Diabetes · Weight Gain
5 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Pramlintide (Symlin) | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | 3.8 to 6.1 kg Weight loss Placebo: 2.8 kg Dose studied: 120, 240, or 360 microg b.i.d. or t.i.d.4 monthsn = 2702008 | −8.4 kg Weight loss · Shown as a change. The study reports a weight loss of this size. Placebo: −2.8 kg Dose studied: 3.0 mg once daily56 weeksn = 3,7312015 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | −0.5% HbA1c change Placebo: −0.5% Dose studied: 15 to 60 microg/meal29 weeksn = 2962006 | −1.48% HbA1c change · liraglutide 1.8 mg |
| Appetite and food intakeMetabolic and weightCompared as: value in the arm that got the peptide, in % | −45% Placebo-corrected binge eating score reduction · Shown as a change. The study reports a placebo-corrected binge eating score reduction of this size. Dose studied: 180 microg before meals6 weeksn = 882007 | |
| Gastrointestinal motilityGastrointestinalCompared as: value in the arm that got the peptide, in min | 268 min Gastric emptying t50% · pramlintide 30 microg t.i.d. (SEM 37) Placebo (SEM 6): 91 min Dose studied: 30 microg t.i.d.5 daysn = 122002 | 70 min Gastric emptying delay median · liraglutide, 5 weeks Placebo, 5 weeks: 4 min |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 55% Hypoglycemia Dose studied: 120 microg24 weeksn = 1132009 | 1% Severe hypoglycemia 5.0 years (mean follow-up)n = 5,0472022 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 63% Nausea Placebo: 36% Dose studied: 15 to 60 microg/meal29 weeksn = 2962006 | 21% Nausea · liraglutide 1.8 mg |
3.8 to 6.1 kg
Weight loss
Placebo: 2.8 kg
Dose studied: 120, 240, or 360 microg b.i.d. or t.i.d.4 monthsn = 2702008
−8.4 kg
Weight loss · Shown as a change. The study reports a weight loss of this size.
Placebo: −2.8 kg
Dose studied: 3.0 mg once daily56 weeksn = 3,7312015
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pramlintide (Symlin) | Liraglutide |
|---|---|---|
| Quality of lifeWhole bodyCompared as: difference from placebo, in points | No comparable result 7 randomized-trial results measure it in another way or another unit. | 3.4 points IWQOL-Lite estimated treatment difference Dose studied: 3.0 mg3 yearsn = 2,210 |
0% Postprandial appetite suppression score change Placebo: −14% 1 yearn = 752022 |
Dose studied: 3·0 mg5 weeksn = 402017
−0.5%
HbA1c change
Placebo: −0.5%
Dose studied: 15 to 60 microg/meal29 weeksn = 2962006
−1.48%
HbA1c change · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 7762013
−45%
Placebo-corrected binge eating score reduction · Shown as a change. The study reports a placebo-corrected binge eating score reduction of this size.
Dose studied: 180 microg before meals6 weeksn = 882007
0%
Postprandial appetite suppression score change
Placebo: −14%
1 yearn = 752022
268 min
Gastric emptying t50% · pramlintide 30 microg t.i.d. (SEM 37)
Placebo (SEM 6): 91 min
Dose studied: 30 microg t.i.d.5 daysn = 122002
70 min
Gastric emptying delay median · liraglutide, 5 weeks
Placebo, 5 weeks: 4 min
Dose studied: 3·0 mg5 weeksn = 402017
55%
Hypoglycemia
Dose studied: 120 microg24 weeksn = 1132009
1%
Severe hypoglycemia
5.0 years (mean follow-up)n = 5,0472022
63%
Nausea
Placebo: 36%
Dose studied: 15 to 60 microg/meal29 weeksn = 2962006
21%
Nausea · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 9112013
| SleepSleepCompared as: difference from placebo, in events h(-1) | No comparable result 3 randomized-trial results measure it in another way or another unit. | −6.1 events h(-1) Estimated treatment difference Dose studied: 3.0 mg32 weeksn = 3592016 |
|---|
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No comparable result 2 randomized-trial results measure it in another way or another unit. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No comparable result 7 randomized-trial results measure it in another way or another unit. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
| Receptor activity and mechanismCardiovascularCompared as: difference from placebo, in proteins | No comparable result 9 randomized-trial results measure it in another way or another unit. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
|---|
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 4 randomized-trial results measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
No comparable result
7 randomized-trial results measure it in another way or another unit.
3.4 points
IWQOL-Lite estimated treatment difference
Dose studied: 3.0 mg3 yearsn = 2,2102018
No comparable result
3 randomized-trial results measure it in another way or another unit.
−6.1 events h(-1)
Estimated treatment difference
Dose studied: 3.0 mg32 weeksn = 3592016
No comparable result
2 randomized-trial results measure it in another way or another unit.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025
No comparable result
7 randomized-trial results measure it in another way or another unit.
21 lipids
Lipids decreased
26 weeksn = 1022021
No comparable result
9 randomized-trial results measure it in another way or another unit.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026
No comparable result
4 randomized-trial results measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011